Patents by Inventor Hogne Vik
Hogne Vik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210220378Abstract: The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NANA are provided for treating or preventing viral infections, such as those causing the common cold.Type: ApplicationFiled: October 11, 2018Publication date: July 22, 2021Inventors: Jan Remmereit, Hogne Vik
-
Patent number: 9730966Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. Further, a method of reducing appetite in humans by administering a krill oil composition is also disclosed.Type: GrantFiled: December 14, 2015Date of Patent: August 15, 2017Assignee: AKER BIOMARINE ANTARTIC ASInventors: Inge Bruheim, Snorre Tilseth, Jeffery Cohn, Mikko Griinari, Sebastiano Banni, Daniele Mancinelli, Nils Hoem, Hogne Vik
-
Publication number: 20160095888Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.Type: ApplicationFiled: December 14, 2015Publication date: April 7, 2016Inventors: Inge Bruheim, Snorre Tilseth, Jeffery Cohn, Mikko Griinari, Sebastiano Banni, Daniele Mancinelli, Nils Hoem, Hogne Vik
-
Patent number: 9220735Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.Type: GrantFiled: April 3, 2014Date of Patent: December 29, 2015Assignee: AKER BIOMARINE ANTARCTIC ASInventors: Inge Bruheim, Snorre Tilseth, Jeffery Cohn, Mikko Griinari, Sebastiano Banni, Daniele Mancinelli, Nils Hoem, Hogne Vik
-
Publication number: 20140363517Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.Type: ApplicationFiled: April 3, 2014Publication date: December 11, 2014Applicant: AKER BIOMARINE ASInventors: Inge BRUHEIM, Snorre TILSETH, Jeffery COHN, Mikko GRIINARI, Sebastiano BANNI, Daniele MANCINELLI, Nils HOEM, Hogne VIK
-
Patent number: 8697138Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.Type: GrantFiled: May 28, 2010Date of Patent: April 15, 2014Assignee: Aker Biomarine ASInventors: Inge Bruheim, Snorre Tilseth, Jeffery Cohn, Mikko Griinari, Daniele Mancinelli, Nils Hoem, Hogne Vik, Sebastiano Banni
-
Publication number: 20140080889Abstract: A method and composition for lipid therapy. In some embodiments, the method comprises providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: GlaxoSmithKline, LLCInventors: George BOBOTAS, Roelof M. Rongen, Egil Bodd, Hogne Vik
-
Publication number: 20110104297Abstract: This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.Type: ApplicationFiled: May 28, 2010Publication date: May 5, 2011Applicant: Aker BioMarine A.S.A.Inventors: Inge BRUHEIM, Snorre Tilseth, Jeffery Cohn, Mikko Griinari, Daniele Mancinelli, Nils Hoem, Hogne Vik, Sebastiano Banni
-
Publication number: 20110092563Abstract: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.Type: ApplicationFiled: December 23, 2010Publication date: April 21, 2011Inventors: George Bobotas, Roelof M. L. Rongen, Egil Bodd, Hogne Vik
-
Publication number: 20100048704Abstract: A pharmaceutical and nutraceutical product is provided comprising vitamin K2 or a compound within the vitamin K2 class of compounds, optionally and preferably in combination with one or more polyunsaturated fatty acids, either in purified form or as a marine oil (i.e. fish and/or krill oil). Also provided is the use of vitamin K2 or a compound within the vitamin K2 class of compounds, preferably in combination with one or more polyunsaturated fatty acids, either in purified form or as a marine oil, in the treatment or prophylaxis of disorders related to bone, cartilage and the cardiovascular system. Preferred compounds within the vitamin K2 class of compounds are MK-7, MK-8, MK-9 and MK-10, in particular MK-7 or MK-9. The marine oil is preferably krill oil or fish oil.Type: ApplicationFiled: July 13, 2007Publication date: February 25, 2010Applicant: NATTOPHARMA ASAInventors: Cees Vermeer, Leon J. Schurgers, Jo Klaveness, Hogne Vik, Anne Bjornebye Vik, Stein Westbye
-
Publication number: 20090239927Abstract: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.Type: ApplicationFiled: October 23, 2008Publication date: September 24, 2009Inventors: George Bobotas, Roelof M. L. Rongen, Egil Bodd, Hogne Vik
-
Publication number: 20090012167Abstract: A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.Type: ApplicationFiled: September 15, 2008Publication date: January 8, 2009Applicants: RELIANT PHARMACEUTICALS, INC., PRONOVA BIOCARE ASInventors: Roelof M. L. RONGEN, George BOBOTAS, Egil BODD, Hogne VIK
-
Publication number: 20070191467Abstract: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.Type: ApplicationFiled: April 30, 2007Publication date: August 16, 2007Applicant: RELIANT PHARMACEUTICAL, INC.Inventors: Roelof Rongen, George Bobotas, Egil Bodd, Hogne Vik
-
Publication number: 20060211762Abstract: A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.Type: ApplicationFiled: November 22, 2005Publication date: September 21, 2006Inventors: Roelof Rongen, George Bobotas, Egil Bodd, Hogne Vik